Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
Status:
Active, not recruiting
Trial end date:
2022-10-21
Target enrollment:
Participant gender:
Summary
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat
outpatient adults with COVID-19 and prevent either severe COVID-19 or death.